# Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

> **NCT05821088** · PHASE2 · RECRUITING · sponsor: **David Bond, MD** · enrollment: 37 (estimated)

## Conditions studied

- Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Recurrent Grade 3b Follicular Lymphoma
- Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
- Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
- Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Recurrent Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
- Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Refractory Grade 3b Follicular Lymphoma
- Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified
- Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
- Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Carboplatin
- **PROCEDURE:** Computed Tomography
- **DRUG:** Etoposide
- **DRUG:** Ifosfamide
- **DRUG:** Lenalidomide
- **PROCEDURE:** Positron Emission Tomography
- **BIOLOGICAL:** Tafasitamab

## Key facts

- **NCT ID:** NCT05821088
- **Lead sponsor:** David Bond, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-29
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05821088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05821088, "Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05821088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*